JPWO2020263651A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020263651A5
JPWO2020263651A5 JP2021576605A JP2021576605A JPWO2020263651A5 JP WO2020263651 A5 JPWO2020263651 A5 JP WO2020263651A5 JP 2021576605 A JP2021576605 A JP 2021576605A JP 2021576605 A JP2021576605 A JP 2021576605A JP WO2020263651 A5 JPWO2020263651 A5 JP WO2020263651A5
Authority
JP
Japan
Prior art keywords
cells
macrophages
bone marrow
agent
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021576605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540768A5 (https=
JP2022540768A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038116 external-priority patent/WO2020263651A1/en
Publication of JP2022540768A publication Critical patent/JP2022540768A/ja
Publication of JP2022540768A5 publication Critical patent/JP2022540768A5/ja
Publication of JPWO2020263651A5 publication Critical patent/JPWO2020263651A5/ja
Pending legal-status Critical Current

Links

JP2021576605A 2019-06-27 2020-06-17 骨髄細胞炎症性表現型を調節するための抗cd53組成物及び方法、ならびにその使用 Pending JP2022540768A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962867602P 2019-06-27 2019-06-27
US62/867,602 2019-06-27
PCT/US2020/038116 WO2020263651A1 (en) 2019-06-27 2020-06-17 Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Publications (3)

Publication Number Publication Date
JP2022540768A JP2022540768A (ja) 2022-09-20
JP2022540768A5 JP2022540768A5 (https=) 2023-06-26
JPWO2020263651A5 true JPWO2020263651A5 (https=) 2023-06-26

Family

ID=74060343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576605A Pending JP2022540768A (ja) 2019-06-27 2020-06-17 骨髄細胞炎症性表現型を調節するための抗cd53組成物及び方法、ならびにその使用

Country Status (10)

Country Link
US (1) US20220251233A1 (https=)
EP (1) EP3990015A4 (https=)
JP (1) JP2022540768A (https=)
KR (1) KR20220042128A (https=)
CN (1) CN114728057A (https=)
AU (1) AU2020304415A1 (https=)
BR (1) BR112021026181A2 (https=)
CA (1) CA3142840A1 (https=)
IL (1) IL289171A (https=)
WO (1) WO2020263651A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102616360B1 (ko) * 2021-11-09 2023-12-27 재단법인 아산사회복지재단 염증성 근육병증 진단용 바이오마커 조성물
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
WO2024220870A1 (en) * 2023-04-19 2024-10-24 The University Of Chicago Antibody-targeted enzymatic chemoprotection
CN117816128B (zh) * 2023-12-15 2025-11-25 华南农业大学 一种重金属检测-吸附一体化复合材料及其制备方法与应用
JP7720659B1 (ja) * 2024-11-15 2025-08-08 宜広 磯貝 骨感染症の血漿バイオマーカー

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100206524B1 (ko) * 1990-07-13 1999-07-01 어니스트 엠. 해데드 씨디 53 세포 표면 항원 및 그를 암호화하는 재조합 디엔에이
WO2002072861A1 (en) * 2001-03-08 2002-09-19 Incyte Genomics, Inc. Cd53 cell surface antigen
US7674598B2 (en) * 2004-05-21 2010-03-09 Beckman Coulter, Inc. Method for a fully automated monoclonal antibody-based extended differential
CN101583722A (zh) * 2006-07-14 2009-11-18 阿维瓦生物科学股份有限公司 从生物学样品检测稀有细胞的方法和组合物
JP7078533B2 (ja) * 2015-10-21 2022-05-31 オーエスイー イムノセラピューティクス 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗SIRPa化合物
JP6967528B2 (ja) * 2016-04-04 2021-11-17 バイオベラティブ ユーエスエー インコーポレイテッド 抗補体Bb因子抗体及びその使用
US20190161542A1 (en) * 2016-08-01 2019-05-30 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
CN111527105B (zh) * 2017-10-11 2024-10-25 美国比奥维拉迪维股份有限公司 诱导补体活性的方法
JP2021529753A (ja) * 2018-06-29 2021-11-04 ヴェルソー セラピューティクス, インコーポレイテッド 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法

Similar Documents

Publication Publication Date Title
Lisi et al. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
JP2026027390A (ja) 腫瘍微小環境の特性を使用するキメラ受容体t細胞治療
JP2023071823A (ja) T細胞療法のために患者をコンディショニングする方法
JP6917903B2 (ja) T細胞療法のための診断方法
CN110290807B (zh) 确定car-t细胞给药的方法
US20220169694A1 (en) Chimeric antigen receptor t cell therapy
JP2022166297A (ja) 最適化された多機能性t細胞を含むキメラ受容体t細胞を使用する治療
JP6944925B2 (ja) 組織浸潤nk細胞を検出する方法
US20250313855A1 (en) Chimeric antigen receptor t cell therapy
TW202238129A (zh) T細胞療法
TW202210084A (zh) Cd30陽性癌症之治療
JP2024507199A (ja) 免疫療法を選択するための遺伝子マーカー
JPWO2020247372A5 (https=)
JPWO2020247371A5 (https=)
JPWO2020263651A5 (https=)
KR20240144434A (ko) 면역요법으로 인한 유해사례 예측
EP3413890A1 (en) Histamine dihydrochloride combinations and uses thereof
JP2023501487A (ja) 白血球上での細胞表面マーカーの発現を制御するための抗Clever-1剤、および抗Clever-1に基づくがん治療を導くためのこれらの使用
JPWO2021243169A5 (https=)
JPWO2020263650A5 (https=)
US20240158869A1 (en) Factors for optimizing immunotherapy
US20250161361A1 (en) Factors for optimizing immunotherapy efficacy
JP2026071229A (ja) 免疫療法由来の有害事象の予測
CN120917153A (zh) 肿瘤微环境对免疫疗法疗效的影响
HK40115765A (zh) 从免疫疗法预测不良事件